Johnson & Johnson

NYSE:JNJ  
167.80
-0.96 (-0.57%)
4:47:30 PM EDT: $168.12 +0.32 (+0.19%)
Products

S.Africa's Aspen Signs Term Sheet On Manufacture And Sale Of Aspen Branded COVID-19 Vaccine

Published: 11/30/2021 12:47 GMT
Johnson & Johnson (JNJ) - Jse: Apn - Aspen Confirms Non-binding Term Sheet on Manufacture and Sale of an Aspen Branded Covid-19 Vaccine Throughout Africa.
Aspen Pharmacare - Aspen Can Sell Finished Form Vaccine Under Aspen Branding to Public Sector Markets in Africa.
Aspen Pharmacare - in Addition, Johnson & Johnson Would Grant Aspen a License to Enabling Intellectual Property for the Purpose.
Aspen Pharmacare - Aspen Sa Plans to Launch This Vaccine Under Brand Name "aspenovax".
Aspen - Deal Grants Aspen Sa Rights to Manufacture Finished Sars-cov-2 Covid-19 Vaccine Product From Drug Substance Supplied by Johnson & Johnson.
Aspen Pharmacare - Term of Grant of Rights and Supply of Drug Substance, Subject to Signing of Definitive Agreement, Would Be Until 31 December 2026.
Jse: Apn - Aspen Confirms Non-binding Term Sheet on Manufacture and Sale of an Aspen Branded Covid-19 Vaccine Throughout Africa.